tiprankstipranks
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
US Market

Spyre Therapeutics (SYRE) Financial Statements

411 Followers

Spyre Therapeutics Financial Overview

Spyre Therapeutics's market cap is currently ―. The company's EPS TTM is $-71.378; its P/E ratio is -0.36; Spyre Therapeutics is scheduled to report earnings on August 8, 2024, and the estimated EPS forecast is $-0.95. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue---$ 688.00K$ 198.00K
Gross Profit---$ 688.00K$ 198.00K
EBIT$ -47.77M$ -47.75M$ -40.10M$ -217.07M$ -18.46M
EBITDA$ -47.77M$ -47.75M-$ -216.67M$ -18.02M
Net Income Common Stockholders$ -43.86M$ -63.18M$ -15.34M$ -217.08M$ -18.42M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 484.64M$ 339.28M$ 203.60M$ 235.36M$ 38.48M
Total Assets$ 487.60M$ 341.86M$ 207.26M$ 243.53M$ 52.45M
Total Debt$ 0.00$ 0.00$ 0.00$ 4.33M$ 4.43M
Net Debt$ -484.64M$ -339.28M$ -203.60M$ -231.03M$ -34.05M
Total Liabilities$ 335.33M$ 73.29M$ 65.56M$ 450.90M$ 18.80M
Stockholders Equity$ 152.27M$ 184.02M$ -245.40M$ -207.37M$ 33.65M
Cash Flow-
Free Cash Flow$ -28.54M$ -31.04M-$ -16.17M$ -17.63M
Operating Cash Flow$ -28.54M$ -31.04M$ -34.60M$ -16.64M$ -17.63M
Investing Cash Flow$ -104.96M$ -35.27M$ -97.63M$ 6.76M$ 17.75M
Financing Cash Flow$ 172.16M$ 163.61M$ -12.53M$ 209.99M$ 10.00K
Currency in USD

Spyre Therapeutics Earnings and Revenue History

Spyre Therapeutics Debt to Assets

Spyre Therapeutics Cash Flow

Spyre Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis